Cardiac Transplant Clinical Trial
Official title:
Cytokine Profiling of Cardiac Transplant Recipients
NCT number | NCT01643564 |
Other study ID # | 1111M06547 |
Secondary ID | |
Status | Terminated |
Phase | |
First received | |
Last updated | |
Start date | November 2011 |
Est. completion date | June 2012 |
Verified date | October 2023 |
Source | University of Minnesota |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Measurement of cytokine levels in post-cardiac transplant patients with unexplained graft dysfunction.
Status | Terminated |
Enrollment | 34 |
Est. completion date | June 2012 |
Est. primary completion date | June 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Group 1 - 18 years and older - Cardiac Transplant recipient with graft dysfunction of unknown etiology Group 2 - 18 years or older - No history of heart failure or cardiac transplantation Group 3 - 18 years or older - Class II-IV heart failure Group 4 - 18 years or older - Heart Transplant 6 months or greater prior to blood draw - No graft dysfunction Exclusion Criteria: Group 1 Heart Transplant with Unexplained Graft Dysfunction - Cellular or antibody-mediated cardiac allograft dysfunction Group 2 Normal Control group - Active infection within 1 month of blood draw - Known Inflammatory Disease Group 3 Heart Failure Group - Active infection within 1 month of blood draw - Known Inflammatory Disease Group 4 Heart Transplant with Normal Graft Function Group - Active infection within 1 month of blood draw - Known graft dysfunction - Known Inflammatory Disease |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Minnesota |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Differences in cytokine profiles between stable heart transplant recipients and those with acute rejection | Differences in cytokine profiles between stable heart transplant recipients and those with acute rejection | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05300451 -
Daratumumab in HLA Desensitization Prior to Transplantation
|
Phase 2 | |
Active, not recruiting |
NCT00695344 -
Study to Evaluate Effect of Everolimus in Progression of Graft Vascular Illness on Patients With Heart Transplant
|
Phase 4 | |
Completed |
NCT02319278 -
DEtection of Cellular Inflammation With FERumoxytol in the HEART
|
Phase 2/Phase 3 | |
Completed |
NCT00480740 -
The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease
|
Phase 3 | |
Active, not recruiting |
NCT03222531 -
Expanding the Pool in Orthotopic Heart Transplantation
|
Phase 2 | |
Terminated |
NCT00041574 -
Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide
|
Phase 2 |